Cytokine gene polymorphisms and the susceptibility to liver cirrhosis in patients with chronic hepatitis C

Liver International

Volumn 23, Issue 6, 2003, Pages 420-425

  Bahr, Matthias J ^a   el Menuawy, Mohamed ^a   Boeker, Klaus H W ^a   Musholt, Petra B ^a   Manns, Michael P ^a   Lichtinghagen, Ralf ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Gene polymorphisms; Hepatitis C; IL1; IL4; Liver cirrhosis; TNF

Indexed keywords

CYTOKINE; DNA; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD DONOR; CAUCASIAN; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GENE LOCUS; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; INTRON; LEUKOCYTE; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; VARIABLE NUMBER OF TANDEM REPEAT;

EID: 0347382508     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2003.00873.x     Document Type: Article

References (44)

1. Lauer G M, Walker B D. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
2. Poynard T, Ratziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34: 730-9.
3. Miyazoe S, Hamasaki K, Nakata K, et al. Influence of interleukin-10 gene promoter polymorphisms on disease progression in patients chronically infected with hepatitis B virus. Am J Gastroenterol 2002; 97: 2086-92.
4. Valenti L, Fracanzani A L, Dongiovanni P, et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 274-80.
5. Donaldson P, Agarwal K, Craggs A, et al. HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis: associations with disease progression and disease susceptibility. Gut 2001; 48: 397-402.
6. Gordon M A, Oppenheim E, Camp N J, et al. Primary biliary cirrhosis shows association with genetic polymorphism of tumour necrosis factor alpha promoter region. J Hepatol 1999; 31: 242-7.
7. Jones D E, Watt F E, Grove J, et al. Tumour necrosis factor-alpha promoter polymorphisms in primary biliary cirrhosis. J Hepatol 1999; 30: 232-6.
8. Tanaka A, Quaranta S, Mattalia A, et al. The tumor necrosis factor-alpha promoter correlates with progression of primary biliary cirrhosis. J Hepatol 1999; 30: 826-9.
9. Fargion S, Valenti L, Dongiovanni P, et al. Tumor necrosis factor alpha promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis. Blood 2001; 97: 3707-12.
10. Mitchell S A, Grove J, Spurkland A, et al. Association of the tumour necrosis factor alpha - 308 but not the interleukin 10 - 627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis. Gut 2001; 49: 288-94.
11. Grove J, Daly A K, Bassendine M F, Day C P. Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology 1997; 26: 143-6.
12. Grove J, Daly A K, Bassendine M F, et al. Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut 2000; 46: 540-5.
13. Takamatsu M, Yamauchi M, Maezawa Y, et al. Genetic polymorphisms of interleukin-1 beta in association with the development of alcoholic liver disease in Japanese patients. Am J Gastroenterol 2000; 95: 1305-11.
14. Gramantieri L, Casali A, Trere D, et al. Imbalance of IL-1 beta and IL-1 receptor antagonist mRNA in liver tissue from hepatitis C virus (HCV)-related chronic hepatitis. Clin Exp Immunol 1999; 115: 515-20.
15. Dumoulin F L, Leifeld L, Honecker U, et al. Intrahepatic expression of interleukin-1 beta and tumor necrosis factor-alpha in chronic hepatitis C. J Infect Dis 1999; 180: 1704-8.
16. Constantini P K, Wawrzynowicz-Syczewska M, Clare M, et al. Interleukin-1, interleukin-10 and tumour necrosis factor-alpha gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to alpha-interferon therapy. Liver 2002; 22: 404-12.
17. Vidigal P G, Germer J J, Zein N N. Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin. J Hepatol 2002; 36: 271-7.
18. Edwards-Smith C J, Jonsson J R, Purdie D M, et al. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 1999; 30: 526-30.
19. Powell E E, Edwards-Smith C J, Hay J L, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000; 31: 828-33.
20. Rosen H R, McHutchison J G, Conrad A J, et al. Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C. Am J Gastroenterol 2002; 97: 714-20.
21. Yee L J, Tang J, Herrera J, et al. Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection. Genes Immun 2000; 1: 386-90.
22. Hulkkonen J, Laippala P, Hurne M. A rare allele combination of the interleukin-1 gene complex is associated with high interleukin-1 beta plasma levels in healthy individuals. Eur Cytokine Netw 2000; 11: 251-5.
23. Hurme M, Santtila S. IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1beta genes. Eur J Immunol 1998; 28: 2598-602.
24. Pociot F, Briant L, Jongeneel C V, et al. Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-alpha and TNF-beta by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. Eur J Immunol 1993; 23: 224-31.
25. Danis V A, Millington M, Hyland V J, Grennan D. Cytokine production by normal human monocytes: intersubject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 1995; 99: 303-10.
26. Santtila S, Savinainen K, Hurme M. Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1beta production in vitro. Scand J Immunol 1998; 47: 195-8.
27. Buchs N, Silvestri T, di Giovine F S, et al. IL-4 VNTR gene polymorphism in chronic polyarthritis. The rare allele is associated with protection against destruction. Rheumatology (Oxford) 2000; 39: 1126-31.
28. Wilson A G, Symons J A, McDowell T L, et al. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997; 94: 3195-9.
29. McDowell T L, Symons J A, Ploski R, et al. A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1 alpha polymorphism. Arthritis Rheum 1995; 38: 221-8.
30. di Giovine F S, Takhsh E, Blakemore A I. Duff G W, Single base polymorphism at - 511 in the human interleukin-1 beta gene (IL1 beta). Hum Mol Genet 1992; 1: 450.
31. Pociot F, Molvig J, Wogensen L, et al. A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest 1992; 22: 396-402.
32. Tarlow J K, Blakemore A I, Lennard A, et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 1993; 91: 403-4.
33. Wilson A G, di Giovine F S, Blakemore A I, Duff G W. Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. Hum Mol Genet 1992; 1: 353.
34. Cantagrel A, Navaux F, Loubet-Lescoulie P, et al. Interleukin-1beta, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms: relationship to occurrence and severity of rheumatoid arthritis. Arthritis Rheum 1999; 42: 1093-100.
35. Lichtinghagen R, Diedrich-Glaubitz R, von Horsten B. Identification of Bordetella pertussis in nasopharyngeal swabs using the polymerase chain reaction: evaluation of detection methods. Eur J Clin Chem Clin Biochem 1994; 32: 161-7.
36. Höhler T, Kruger A, Gerken G, et al. A tumor necrosis factor-alpha (TNF-alpha) promoter polymorphism is associated with chronic hepatitis B infection. Clin Exp Immunol 1998; 111: 579-82.
37. Galbraith G M, Pandey J P. Tumor necrosis factor alpha (TNF-alpha) gene polymorphism in Alopecia areata. Hum Genet 1995; 96: 433-6.
38. Rudwaleit M, Tikly M, Khamashta M, et al. Interethnic differences in the association of tumor necrosis factor promoter polymorphisms with systemic Lupus erythematosus. J Rheumatol 1996; 23: 1725-8.
39. Hacker U T, Bidlingmaier C, Gomolka M, et al. Inflammatory bowel disease: no association between allele combinations of the interleukin (IL) I beta and IL-I receptor antagonist gene polymorphisms. Eur J Clin Invest 1998; 28: 214-9.
40. Muhlberg T, Kirchberger M, Spitzweg C, et al. Lack of association of Graves' disease with the A2 allele of the interleukin-1 receptor antagonist gene in a white European population. Eur J Endocrinol 1998; 138: 686-90.
41. Huang D, Xia S, Zhou Y, et al. No evidence for interleukin-4 gene conferring susceptibility to myasthenia gravis. J Neuroimmunol 1998; 92: 208-11.
42. Rosen H R, Lentz J J, Rose S L, et al. Donor polymorphism of tumor necrosis factor gene: relationship with variable severity of hepatitis C recurrence after liver transplantation. Transplantation 1999; 68: 1898-902.
43. Fukuda R, Ishimura N, Ishihara S. et al. Intrahepatic expression of pro-inflammatory cytokine mRNAs and interferon efficacy in chronic hepatitis C. Liver 1996; 16: 390-9.
44. Napoli J, Bishop G A, McGuinness P H, et al. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 1996; 24: 759-65.